

Clinical Oversight Review Board (CORB) Criteria for Prescribing/ **sutimlimab-jome (Enjaymo)**

Notes:

- * Intolerance excludes adverse drug reactions that are expected, mild in nature, resolve with continued treatment, and do not require medication discontinuation

Notes: Requires interregional consultative physician review after 2 months of treatment for ongoing treatment

Non-Formulary **sutimlimab-jome (Enjaymo)** requires a clinical review. Appropriateness of therapy will be based on the following criteria:

Initiation (new start) criteria: Non-Formulary **sutimlimab-jome (Enjaymo)** will be covered on the prescription drug benefit for 2 months when the following criteria are met:

- Patient has a diagnosis of Cold agglutinin disease (CAD)
- Prescribed by hematology provider
- Patient is 18 years old or older
- Bilirubin level above the normal reference range
- Either of the following:
 - If acute anemia from CAD: Patient with symptomatic anemia or need for transfusion -AND- awaiting for rituximab +/- bendamustine treatment to take effect
 - If chronic anemia from CAD: patient with symptomatic anemia or need for transfusion -AND- not responding adequately to treatment with rituximab +/- bendamustine

Criteria for *current Kaiser Permanente members -AND- new members already taking the medication who have not been reviewed previously:* Non-Formulary sutimlimab-jome (Enjaymo) will be covered on the prescription drug benefit when the following criteria are met:

- An Interregional Consultative Physician Panel review is recommended to reassess the need for ongoing treatment with sutimlimab-jome after a patient has been on treatment for two months.